Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

The best ever GOG data no longer best ever...

I posted this re: cervical cancer:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148860292

ADXS cervical cancer data no longer looks impressive.
When ADXS issued a PR in '15 about the cervical data, they touted the 52% improvement over "median" OS results, and reluctantly hid the overall response rates (ORR). Their ORR is as follows:
GOG 0265 data was: CR:=1; SD:=15, out of 50 patients. ORR:=32%
Now, IOVA presented data at ASCO:
"Preliminary results from a Phase 2 study, innovaTIL-04, assessing lead candidate LN-145 in patients with recurrent/metastatic/refractory cervical cancer (average of 2.6 prior lines of therapy) showed a 44% response rate (n=12/27) and a disease control rate (DCR) (responders + stable cancer) of 89% (n=24/27). 11 of the 12 responders maintained their responses at a median follow-up of 3 1/2 months. By comparison, the response rate for Merck's (NYSE:MRK) Keytruda in second-line cervical cancer is 14%"

You don't have to be Hovacre to figure out that the GOG data is weak now. This explains a drop today.
https://seekingalpha.com/news/3464495-iovance-28-percent-premarket-positive-til-data